IBRNvsIDNA
iShares Neuroscience and Healthcare ETF against iShares Genomics Immunology and Healthcare ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IBRN | IDNA | |
|---|---|---|
| Expense ratio | 0.47% | 0.47% |
| Assets | $7931.50T | $218M |
| Net flow, 1 month | +$2M | +$7M |
| Net flow, 1 year | +$2M | +$36M |
| Return, YTD | +27.9% | +55.4% |
| Return, 1 year | — | — |
| Avg daily volume | 3K | 42K |
| Holdings | 54 | 63 |
| Listed | Aug 23, 2022 | Jun 10, 2019 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS